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Objective: The inflammatory process of aortic stenosis involves the differentiation of aortic valve myofibroblasts
into osteoblasts. Osteopontin, a proinflammatory glycoprotein, both stimulates differentiation of myofibroblasts
and regulates the deposition of calcium by osteoblasts. Osteopontin levels are increased in patients with such con-
ditions as end-stage renal disease, ectopic calcification, and autoimmune disease. We hypothesized that increased
plasma osteopontin levels might be associated with the presence of aortic valve calcification and stenosis.
Methods: Venous blood from volunteers older than 65 years undergoing routine echocardiographic analysis or
aortic valve surgery for aortic stenosis was collected. Plasma osteopontin levels were measured by means of en-
zyme-linked immunosorbent assay. The presence of aortic stenosis was defined as an aortic valve area of less than
2.0 cm2. Aortic valve calcification was assessed by using a validated echocardiographic grading system (1, none;
2, mild; 3, moderate; 4, severe). Comparisons were performed with nonpaired t tests.
Results: Aortic stenosis was present in 23 patients (mean age, 78 years) and was absent in 7 patients (mean age,
72 years). Aortic valve calcification scores were 3.5  0.6 and 1.3  0.5 in patients with and without aortic ste-
nosis, respectively (P< .001). Patients with no or mild aortic valve calcification had lower osteopontin levels
compared with patients with moderate or severe aortic valve calcification (406.1  165.8 vs 629.5  227.5
ng/mL, P ¼ .01). Similarly, patients with aortic stenosis had higher osteopontin levels compared with patients
without aortic stenosis (652.2  218.7 vs 379.7  159.9 ng/mL, P< .01).
Conclusion: Increased levels of plasma osteopontin are associated with the presence of aortic valve calcification
and stenosis. These findings suggest that osteopontin might play a functional role in the pathogenesis of calcific
aortic stenosis.
Perioperative Management Yu et alAortic valve calcification is a prevalent condition that is
found in 21% to 26% of adults older than 65 years.1,2 In ad-
dition to being independently associated with an increased
risk of death from cardiovascular causes, the degree of aortic
valve calcification has also been correlated with the presence
and progression of calcific aortic stenosis.3,4 With a preva-
lence of 3% to 9%, calcific aortic stenosis is also the most
prevalent valvular disease and the main cause for valve
replacement in patients older than 60 years. Although
calcific aortic stenosis is a gradually progressive disease
characterized by a long asymptomatic phase, severe symp-
tomatic aortic stenosis is associated with a life expectancy
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definitive treatment for aortic stenosis. Despite the high
prevalence and mortality associated with both aortic valve
calcification and stenosis, little is known about the molecular
mechanisms driving their pathogenesis.
The development of calcific aortic valve disease is charac-
terized by 3 primary processes: lipid accumulation,6 inflam-
mation,7-9 and ultimately calcification.10 The finding that the
multifunctional glycophosphoprotein osteopontin (OPN) is
involved in both cell-mediated inflammation and biominer-
alization has generated considerable interest in the role of
OPN in ectopic calcification and calcific aortic valve disease.
In the present study we describe the association between
increased plasma OPN levels and the presence of aortic
valve calcification and stenosis.
MATERIALS AND METHODS
Patient Selection
Between April 2007 and September 2007, venous blood specimens were
collected from patients undergoing routine echocardiographic analysis and
from patients undergoing scheduled aortic valve surgery. Institutional re-
view board approval (H#07-086) and informed consent were obtained.urgery c July 2009
P
M
Yu et al Perioperative ManagementAbbreviation and Acronym
OPN ¼ osteopontin
Clinical information was obtained by means of patient interview and chart
review. Patient selection was limited to those older than 65 years. Exclusion
criteria included patients with serum creatinine values of 1.5 mg/dL or
greater; bicuspid aortic valve; premature menopause, osteoporosis, or
both; prior aortic valve surgery; rheumatic heart disease; endocarditis; active
malignancy; chronic liver failure; calcium regulation disorders (hyperpara-
thyroidism, hyperthyroidism, and hypothyroidism); and chronic or acute in-
flammatory states (sepsis, autoimmune disease, and inflammatory bowel
disease).
OPN Measurement
Ethylenediamine tetra-acetic acid–anticoagulated blood specimens were
immediately centrifuged, and the plasma was stored at80C. Plasma OPN
levels were measured in batches by means of enzyme-linked immunosor-
bent assay with a commercially available kit (Human Osteopontin Assay
Kit; Immuno-Biological Laboratories, Minneapolis, Minn), according to
the manufacturer’s instructions.
Echocardiographic Analysis
All patients had a comprehensive echocardiographic assessment, includ-
ingM-mode, 2-dimensional, and color Doppler echocardiographic analysis,
conducted by a certified echocardiographer with commercially available ul-
trasound systems. All measurements were performed according to the
American Society of Echocardiography’s recommendations.11 The pres-
ence of aortic stenosis was defined as an aortic valve area of less than 2.0
cm2. Aortic valve calcification was assessed, and a calcium score of 1 to
4 was assigned for each patient by a single cardiologist (GP) based on the
method described by Rosenhek and colleagues12: 1, no calcification; 2,
mildly calcified (small isolated spots); 3, moderately calcified (multiple
larger spots); and 4, severely calcified (extensive thickening and calcifica-
tion of all cusps).
Statistical Analysis
Statistical analysis was performed with the statistical software SPSS
(Version 15; SPSS, Inc, Chicago, Ill). Continuous variables were analyzed
by using the Student’s t test and categorical variables by using the c2 test.
Linear and logistic regression analyses were used to determine the correla-
tion between 2 variables.
RESULTS
Aortic stenosis was present in 23 patients and was absent
in 7 patients. Demographic and clinical characteristics of pa-
tients with aortic stenosis and control subjects are shown in
Table 1. There were no significant differences in the sex,
age, comorbidities, blood calcium levels, and calcium–phos-
phorus product between the 2 groups. Of the patients with
aortic stenosis, the average aortic valve area and mean gra-
dient were 0.78  0.28 cm2 and 37.12  19.08 mm Hg,
respectively. Patients with aortic stenosis had higher aortic
valve calcification scores compared with control subjects
(3.5  0.6 vs 1.3  0.5, P< .001).
Plasma OPN levels were increased in patients with moder-
ate-to-severe aortic valve calcification compared with those
seen in patients with no or mild aortic valve calcificationThe Journal of Thoracic and C(629.5 227.5 vs 406.1 165.8 ng/mL, P¼ .01; Figure 1).
Logistic regression of OPN level, age, and adjusted serum
calcium level showed only OPN level to be independently as-
sociated with degree of aortic valve calcification (P ¼ .04).
Plasma OPN levels were also significantly increased in pa-
tients with aortic stenosis comparedwith those in control sub-
jects (652.2  218.7 vs 379.7  159.9 ng/mL, P< .01;
Figure 2). Linear regression analysis showed that plasma
OPN levels significantly but weakly correlated with
the degree of aortic stenosis (r ¼ 0.41, P ¼ .03).
DISCUSSION
The prevalence of aortic valve calcification increases with
age. It is found in 26% of those older than 65 years and 37%
of those older than 75 years.2 Even after adjustment for as-
sociated clinical factors, such as age, male sex, smoking,
and dyslipidemia, aortic valve calcification is associated
with an increased risk of death from cardiovascular causes.13
Aortic valve calcification, with or without aortic stenosis,
therefore constitutes a significant health problem.
A study conducted by Rosenhek and colleagues12 found
valvular calcification to be the only independent predictor
of outcome in patients with severe aortic stenosis. They
TABLE 1. Demographic and clinical characteristics of patients with
aortic stenosis and control subjects
Characteristics
Aortic stenosis
(n ¼ 23)
Control subjects
(n ¼ 7)
P
value
Age (y) 78  7.9 72  7.1 .09
Male sex 11 (47.8%) 4 (57.1%) .66
Smokers 8 (34.8%) 1 (14.3%) .57
Hypertension 17 (78.3%) 7 (100%) .44
Diabetes mellitus 8 (34.8%) 3 (42.9%) 1.00
CVA 1 (4.3%) 1 (14.3%) .95
PVD 2 (8.7%) 1 (14.3%) 1.00
Coronary artery disease 9 (39.1%) 1 (14.3%) .45
Hyperlipidemia 13 (56.5%) 5 (71.4%) .79
AVC score 3.5  0.6 1.3  0.5 <.001
Adjusted calcium (mg/dL) 9.2  0.5 9.3  0.6 .86
CaxP 32.7  5.0 31.3  6.7 .69
CVA, Cerebral vascular accident; PVD, peripheral vascular disease; AVC, aortic valve
calcification; CaxP, calcium–phosphorus product.
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FIGURE 1. Correlation between circulating osteopontin (OPN) levels and
aortic valve calcification. Error bars: 1 standard error. *P ¼ .01.ardiovascular Surgery c Volume 138, Number 1 197
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patients with no or mild valvular calcification compared with
those with moderate or severe calcification. Patients with
moderate calcification had similar outcomes to those with
severe calcification. By using the same aortic valve calcifica-
tion scoring and categorization system, our study found
increased levels of plasma OPN levels in patients with
moderate-to-severe aortic valve calcification compared
with those with no to mild calcification. This finding might
suggest a future role of plasma OPN levels to risk stratify
patients with aortic valve calcification, stenosis, or both for
either closer follow-up or earlier surgical intervention.
Both in vitro and in vivo studies have shown that valvular
calcification is an active process controlled by inflammatory
mediators, the balance between osteoblast-like differentia-
tion and osteoclast recruitment at the tissue level, as well
as levels of bone matrix proteins, such as OPN (Figure 3).
The hemodynamic severity and progression of aortic steno-
sis is well correlated with both the presence and degree of
aortic valve calcification.3,12,14 Increased OPN expression
has been found in hypercholesterolemia-induced atheroscle-
rosis and osteoblast-like changes in rabbit aortic valves.15
High levels of OPN in native human calcified degenerative
aortic valves from patients undergoing valve replacement
have been shown by means of immunohistochemistry, re-
verse transcription–polymerase chain reaction, Western
blotting, and in situ hybridization analyses.16-18 OPN local-
izes with macrophages and areas of calcium deposition and
varies in proportion to the amount of calcium present.16,17 In
addition to native valves, increased OPN levels were also
found by means of immunohistochemistry in calcified valve
allografts.19 Similarly, immunostaining and Western blot
analysis of explanted glutaraldehyde-pretreated biopros-
thetic porcine valves has shown higher OPN levels in calci-
fied compared with noncalcified areas.20 It is thus speculated
that calcification of the originally acellular bioprosthesis
might involve adsorption of proteins, such as OPN from cir-
culating blood.
High levels of circulating OPN have been found in cardio-
vascular diseases, such as atherosclerosis, ischemic heart
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FIGURE 2. Correlation between circulating osteopontin (OPN) levels and
aortic stenosis. Error bars: 1 standard error. *P< .01.198 The Journal of Thoracic and Cardiovascular Surdisease, heart failure, and rheumatic mitral stenosis.21-24 In
the present study we describe an association between in-
creased levels of plasmaOPN and both aortic valve calcifica-
tion and the degree of aortic stenosis. Although other serum
markers, such as C-reactive protein,25 calcium–phosphate
product,26 and B-type natriuretic peptide27 have previously
been shown to be associated with aortic calcification and
stenosis, OPN is the only molecule that is implicated in
both inflammation and biomineralization processes, which
lead to aortic valve calcification and subsequent stenosis.
Therefore our findings suggest that OPNmight play a unique
functional role in the pathogenesis of calcific aortic stenosis.
A potential limitation of this study is the semiquantitative
nature of the aortic valve calcification scoring system: this
variability was minimized by assigning a single blinded
cardiologist to the grading of calcium scores. Another limi-
tation is the small study size; although statistically signifi-
cant, the possibility of type 1 error exists because of other
unmeasured cofactors. Importantly, this study was limited
to the quantitative assessment of plasma OPN in the pres-
ence of aortic valve calcification and stenosis. However,
posttranslational modifications of OPN, such as phosphory-
lation, are key modulators of the biologic function of OPN.
Therefore the role of OPN in the development of ectopic
calcification might not depend simply on the amount of cir-
culating OPN levels but additionally on the qualitative mod-
ification of the molecule. Cell cultures have demonstrated
that exogenous OPN inhibits in vitro calcification of smooth
muscle cells.28 Additionally, in vivo studies with OPN mu-
tant mice further demonstrate that OPN not only inhibits but
also promotes active dissolution of ectopic calcification. In
FIGURE 3. Pathogenesis of aortic valve calcification. Active processes in-
volving lipid accumulation, inflammation, and calcification leading to the
formation of calcific valvular disease are shown. IL-1, Interleukin 1; LDL,
low-density lipoprotein; MV, macrophage; MMP, matrix metalloprotei-
nase; OPN, osteopontin; RANK, receptor activator of nuclear factor kB;
TGF, transforming growth factor; TNF, tumor necrosis factor.gery c July 2009
Yu et al Perioperative Managementspite of this, our study and previous studies have found in-
creased levels of OPN in the plasma and valvular tissue of
patients with aortic valve calcification and stenosis. These
seemingly opposing biologic effects of OPN might be de-
pendent on posttranslational modifications of the molecule.
Therefore future studies of the molecular role of OPN in
valve calcification might provide new opportunities to mod-
ify the progression of aortic valve calcification and stenosis.
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